Event-Driven Stocks

Candel Therapeutics, Inc.

CADLNasdaq

Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 1 good● 1 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue———$125,000$125,000$125,000
Operating income−$48.3M−$33.4M−$38.4M−$34.7M−$25.7M−$13.8M
Net income−$38.2M−$55.2M−$37.9M−$18.8M−$36.1M−$17.7M
Total assets$125.2M$106.9M$41.2M$77.7M$89.2M$38.3M
Total liabilities$73.3M$40.5M$28.5M$30.0M$25.1M$12.8M
Equity$51.9M$66.3M$12.7M$47.7M$64.1M−$23.6M
EPS (diluted)$-0.72$-1.74$-1.31$-0.65$-1.91—
Shares out.47.2M29.3M28.9M28.7M28.7M11.6M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
—
Net margin
—
Return on equity
−73.5%
Return on assets
−30.5%
Return on capital (ROCE)
−41.5%
Liabilities / assets
58.5%
Debt / equity
1.41×
Book value / share
$1.10
Revenue growth (YoY)
—
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-1.96distress
Accruals / assets
0.1%clean
Piotroski F-Score
2/7weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
52
/ 100
Profitability 0Growth n/aCatalyst 100Earnings quality 33Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 1 warning● 1 good
  • Altman Z″ in the distress zone
  • Negative operating cash flow
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Insider transactions

SEC Form 4 · most recent
2 acquisitions0 disposals1 open-market buy(s)net +551,395 shares · last 2
InsiderDateTypeSharesPrice
Manning Paul BDirectorFeb 23, 2026Buy550,458$5.45
Nichols William GarrettOfficer — Chief Medical OfficerJul 28, 2025Option exercise937$1.29

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 202614.4M5.5-1.8%
Apr 30, 202614.7M6.4-2.6%
Apr 15, 202615.1M15.5+1.7%
Mar 31, 202614.8M11.7+4.5%
Mar 13, 202614.2M11.1+9.2%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (2)